Page 278 - Read Online

Russo et al. Hepatoma Res 2018;4:25 I http://dx.doi.org/10.20517/2394-5079.2018.52 Page 7 of 14

Carrat et al. [23] (1) 267 patients with (1) 20 NA NA (1) 24/189 (1) 16/78 NA NA
(French) previous history of (0.73/100 untreated
HCC (HEPATHER person-month) (0.66/100
cohort): person-
• 189 (2) 1/13 (1.1/100 month)
treated person-month)
• 78 (2) 31/66
untreated (2) 59 untreated
(1.73/100
(2) 79 patients with person-
previous history of month)
HCC (CirVr cohort)
• 13 treated
• 66 (3) 70
untreated
(3) 214 patient who
underwent LT for
HCC treated (CUPILT
cohort)
Cheung et al. [24] 406 cirrhotic 6-15 15/288 11/261 2/18 0/11 NA NA
(UK) patients [29 (7.1%) (range) (5.2%) (4.2%) (11.1%) (0%)
with baseline HCC]
with decompensated
cirrhosis (317
achieved SVR 24)
Torres et al. [25] Prospective 12 months* NA NA No recurrence NA NA NA
(USA) observational study
of 8 patients with *From
HCC (curative DAA start
treatment#) treated
(1 non cirrhotic)
#DAA not offered
to patients receiving
palliative treatment
(i.e., TACE)
Zavaglia et al. [26] 31 patients (4 8 NA NA 1* (3.2%) NA Not reported NA
(Italy) patients underwent months*
LT during FU) *Median time
*From interval between
DAA start HCC complete
eradication
and the start of
therapy was 19.3
months

[31]
Kobayashi et al. SVR + patients 48 2 (2.6%) in NA NA NA NA
(Japan) *#(retrospective DAA group
evaluation):
• 77 DAA 5-year 5-year
• 528 Peg- cumulative cumulative
IFN/RBV HCC HCC
development development
*No previous history rate 3% rates 2.2% (P
of HCC = NS)
#Fib-4 score > 3.25
in 29.9% and 14.8%,
respectively (< In high Fib- In high Fib-4
0.001) 4 score group 5-year
group 5-year cumulative
cumulative rate was 8.4%
rate was (P = NS)
9.7%
Petta et al. [33] SVR + patients: 18 (DAA) 16 (28%) 22 (39%) NA NA NA NA
(Italy) • 58 DAA 34 (Peg-
• 57 Peg- IFN/RBV)
IFN/RBV